Nantong University
13
1
1
2
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
15%
2 trials in Phase 3/4
0%
0 of 2 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Effectiveness of Health Literacy Enhancement Program Among Older Persons With Physical Multimorbidity
Role: lead
Promoting Medication Reimbursement Policy (PAPMed)
Role: collaborator
Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors
Role: collaborator
Genomic Study of Relapse Esophageal Cancer After Radiotherapy
Role: collaborator
Real World Study of Classic Infectious Disease
Role: collaborator
Clinical Study of Kangfuxin and Basic Fibroblast Growth Factor in Promoting the Healing of Donor Site
Role: collaborator
Lung Cancer Rehabilitation After Medical Treatment
Role: lead
Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer
Role: collaborator
Chinese TaTME Registry Collaborative
Role: collaborator
Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency
Role: collaborator
Digital Navigation Enhances Cervical Pedicle Screw Placement Accuracy and Safety
Role: lead
Corticosteroid Therapy for Severe Community-Acquired Pneumonia
Role: collaborator
A Comparison of Recombinant Human Brain Natriuretic Peptide and Dobutamine
Role: lead
All 13 trials loaded